NIKKEI 225
38,785.44 -137.59 (-0.35%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.02 -0.20 (-0.27%) GOLD FUTURES
2,371.60 +2.30 (+0.10%) DOW
38,571.03 -115.29 (-0.30%) Bitcoin GBP
53,675.73 +893.80 (+1.69%)
The fight against COVID19
23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The fight against COVID19 | +2.10% | - | - | - |
| ^GSPC | +0.11% | +1.98% | +23.62% | +5581.07% |
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 147.74 | +1.07 | +0.73% | 16:00 GMT-4 | 5.29M | 7.70M | 355.56B |
| ABBV | AbbVie Inc. | 160.19 | -1.05 | -0.65% | 16:00 GMT-4 | 3.37M | 5.78M | 282.87B |
| PFE | Pfizer Inc. | 29.31 | +0.65 | +2.27% | 16:01 GMT-4 | 29.23M | 42.12M | 166.09B |
| SNY | Sanofi | 49.25 | +0.22 | +0.45% | 16:00 GMT-4 | 1.71M | 1.98M | 123.09B |
| REGN | Regeneron Pharmaceuticals, Inc. | 989.48 | +9.32 | +0.95% | 16:00 GMT-4 | 513.40k | 440.60k | 109.03B |
| GSK | GlaxoSmithKline plc | 40.88 | -3.89 | -8.69% | 16:00 GMT-4 | 12.40M | 3.12M | 83.35B |
| GILD | Gilead Sciences, Inc. | 63.43 | -0.84 | -1.31% | 16:00 GMT-4 | 8.18M | 7.04M | 79.02B |
| MRNA | Moderna, Inc. | 147.82 | +5.27 | +3.70% | 16:00 GMT-4 | 4.92M | 4.06M | 56.65B |
| TAK | Takeda Pharmaceutical Company Limited | 13.36 | +0.01 | +0.07% | 16:00 GMT-4 | 1.92M | 1.57M | 41.92B |
| BNTX | BioNTech SE | 102.87 | +2.27 | +2.26% | 16:00 GMT-4 | 940.12k | 723.66k | 24.79B |
| NVAX | Novavax, Inc. | 18.22 | +3.19 | +21.22% | 16:00 GMT-4 | 27.78M | 12.48M | 2.68B |
| VIR | Vir Biotechnology, Inc. | 10.63 | +0.36 | +3.51% | 16:00 GMT-4 | 937.14k | 889.63k | 1.45B |
| INO | Inovio Pharmaceuticals, Inc. | 10.16 | +0.03 | +0.30% | 16:00 GMT-4 | 215.81k | 427.41k | 263.25M |
- Yahoo Finance Video
GameStop rally, NYSE glitch, Best Buy upgrade: Market Domination
Stocks ended the day mixed (^DJI,^GSPC, ^IXIC), with the Dow Jones Industrial Average closing lower by 115 points while the S&P 500 and Nasdaq both posted gains. One of the biggest movers of the day was GameStop (GME), which saw its shares soar 21% after an account linked to meme stock trader Keith Gill, also known as "Roaring Kitty," posted a screenshot of a trading account with a $175 million stake in the video game retailer. The Wall Street Journal is now reporting that E-Trade is considering removing Gill from its platform over concerns about potential market manipulation. On the latest Market Domination, Jared Blikre reports on the NYSE glitch that showed Berkshire Hathaway Class A (BRK-A) shares down 99.9% at one point, Alexandra Canal breaks down the latest on the Skydance/Paramount (PARA, PARAA) deal, and Anjalee Khemlani discusses what the latest FDA consideration on Covid booster shots means for Novavax (NVAX). Julie Hyman and Josh Lipton discuss analyst calls on Tractor Supply Company (TSCO) and Best Buy (BBY). Finally, Rockland Trust Vice President and Portfolio Manager Michael Sayers and Halo Investing President Jason Barserma discuss some of their top plays ahead of the Federal Reserve's next rate decision. For more expert insight and the latest market action, click here. This post was written by Stephanie Mikulich.
ZacksAbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
In the most recent trading session, AbbVie (ABBV) closed at $160.19, indicating a -0.65% shift from the previous trading day.
BenzingaGSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex for relapsed or refractory multiple myeloma. The data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On the primary endpoint of progression-free survival (PFS), the belantamab mafodotin comb
